Radionuclide imaging of infection

Charito Love, Christopher J. Palestro

Research output: Contribution to journalArticle

150 Citations (Scopus)

Abstract

Although our understanding of microorganisms has advanced significantly and antimicrobial therapy has become increasingly available, infection remains a major cause of patient morbidity and mortality. The role of radionuclide imaging in the evaluation of the patient suspected of harboring an infection varies with the situation. For example, in the postoperative patient, radionuclide imaging is complementary to CT and is used to help differentiate postoperative changes from infection. In the case of the painful joint replacement, in contrast, radionuclide studies are the primary diagnostic imaging modality for differentiating infection from other causes of prosthetic failure. Several tracers are available for imaging infection: 99mTc-diphosphonates, 67Ga-citrate, and 111In- and 99mTc-labeled leukocytes. At the moment, in immunocompetent patients, labeled leukocyte imaging is the radionuclide procedure of choice for detecting most infections. There are, unfortunately, significant limitations to the use of labeled leukocytes. The in vitro labeling process is labor intensive, is not always available, and involves direct handling of blood products. For musculoskeletal infection, the need to frequently perform complementary marrow or bone imaging adds complexity and expense to the procedure and is an inconvenience to patients. Considerable effort has therefore been devoted to the search for alternatives to this procedure, including in vivo methods of labeling leukocytes, 18F-FDG PET, and radiolabeled antibiotics. This article reviews the current status of nuclear medicine infection imaging and the potential of a murine monoclonal antigranulocyte antibody, fanolesomab, that is currently under investigation. Upon completion of this article, the reader will be familiar with the physical characteristics and uptake mechanisms of tracers currently approved for infection imaging, the indications for the uses of these tracers, and the characteristics and potential indications for a murine monoclonal antigranulocyte antibody under investigation.

Original languageEnglish (US)
Pages (from-to)47-57
Number of pages11
JournalJournal of Nuclear Medicine Technology
Volume32
Issue number2
StatePublished - Jun 2004
Externally publishedYes

Fingerprint

Radionuclide Imaging
Infection
Leukocytes
Replacement Arthroplasties
Monoclonal Antibodies
Nuclear Medicine
Fluorodeoxyglucose F18
Diphosphonates
Diagnostic Imaging
Citric Acid
Radioisotopes
Bone Marrow
Anti-Bacterial Agents
Morbidity
Mortality

Keywords

  • Antigranulocyte antibodies
  • Bone
  • Gallium
  • Infection
  • Infectious disease
  • Labeled leukocytes
  • Monoclonal antibodies

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Radionuclide imaging of infection. / Love, Charito; Palestro, Christopher J.

In: Journal of Nuclear Medicine Technology, Vol. 32, No. 2, 06.2004, p. 47-57.

Research output: Contribution to journalArticle

Love, C & Palestro, CJ 2004, 'Radionuclide imaging of infection', Journal of Nuclear Medicine Technology, vol. 32, no. 2, pp. 47-57.
Love, Charito ; Palestro, Christopher J. / Radionuclide imaging of infection. In: Journal of Nuclear Medicine Technology. 2004 ; Vol. 32, No. 2. pp. 47-57.
@article{a13c155e2639480b8fa6e8126b6eefc6,
title = "Radionuclide imaging of infection",
abstract = "Although our understanding of microorganisms has advanced significantly and antimicrobial therapy has become increasingly available, infection remains a major cause of patient morbidity and mortality. The role of radionuclide imaging in the evaluation of the patient suspected of harboring an infection varies with the situation. For example, in the postoperative patient, radionuclide imaging is complementary to CT and is used to help differentiate postoperative changes from infection. In the case of the painful joint replacement, in contrast, radionuclide studies are the primary diagnostic imaging modality for differentiating infection from other causes of prosthetic failure. Several tracers are available for imaging infection: 99mTc-diphosphonates, 67Ga-citrate, and 111In- and 99mTc-labeled leukocytes. At the moment, in immunocompetent patients, labeled leukocyte imaging is the radionuclide procedure of choice for detecting most infections. There are, unfortunately, significant limitations to the use of labeled leukocytes. The in vitro labeling process is labor intensive, is not always available, and involves direct handling of blood products. For musculoskeletal infection, the need to frequently perform complementary marrow or bone imaging adds complexity and expense to the procedure and is an inconvenience to patients. Considerable effort has therefore been devoted to the search for alternatives to this procedure, including in vivo methods of labeling leukocytes, 18F-FDG PET, and radiolabeled antibiotics. This article reviews the current status of nuclear medicine infection imaging and the potential of a murine monoclonal antigranulocyte antibody, fanolesomab, that is currently under investigation. Upon completion of this article, the reader will be familiar with the physical characteristics and uptake mechanisms of tracers currently approved for infection imaging, the indications for the uses of these tracers, and the characteristics and potential indications for a murine monoclonal antigranulocyte antibody under investigation.",
keywords = "Antigranulocyte antibodies, Bone, Gallium, Infection, Infectious disease, Labeled leukocytes, Monoclonal antibodies",
author = "Charito Love and Palestro, {Christopher J.}",
year = "2004",
month = "6",
language = "English (US)",
volume = "32",
pages = "47--57",
journal = "Journal of Nuclear Medicine Technology",
issn = "0091-4916",
publisher = "Society of Nuclear Medicine Inc.",
number = "2",

}

TY - JOUR

T1 - Radionuclide imaging of infection

AU - Love, Charito

AU - Palestro, Christopher J.

PY - 2004/6

Y1 - 2004/6

N2 - Although our understanding of microorganisms has advanced significantly and antimicrobial therapy has become increasingly available, infection remains a major cause of patient morbidity and mortality. The role of radionuclide imaging in the evaluation of the patient suspected of harboring an infection varies with the situation. For example, in the postoperative patient, radionuclide imaging is complementary to CT and is used to help differentiate postoperative changes from infection. In the case of the painful joint replacement, in contrast, radionuclide studies are the primary diagnostic imaging modality for differentiating infection from other causes of prosthetic failure. Several tracers are available for imaging infection: 99mTc-diphosphonates, 67Ga-citrate, and 111In- and 99mTc-labeled leukocytes. At the moment, in immunocompetent patients, labeled leukocyte imaging is the radionuclide procedure of choice for detecting most infections. There are, unfortunately, significant limitations to the use of labeled leukocytes. The in vitro labeling process is labor intensive, is not always available, and involves direct handling of blood products. For musculoskeletal infection, the need to frequently perform complementary marrow or bone imaging adds complexity and expense to the procedure and is an inconvenience to patients. Considerable effort has therefore been devoted to the search for alternatives to this procedure, including in vivo methods of labeling leukocytes, 18F-FDG PET, and radiolabeled antibiotics. This article reviews the current status of nuclear medicine infection imaging and the potential of a murine monoclonal antigranulocyte antibody, fanolesomab, that is currently under investigation. Upon completion of this article, the reader will be familiar with the physical characteristics and uptake mechanisms of tracers currently approved for infection imaging, the indications for the uses of these tracers, and the characteristics and potential indications for a murine monoclonal antigranulocyte antibody under investigation.

AB - Although our understanding of microorganisms has advanced significantly and antimicrobial therapy has become increasingly available, infection remains a major cause of patient morbidity and mortality. The role of radionuclide imaging in the evaluation of the patient suspected of harboring an infection varies with the situation. For example, in the postoperative patient, radionuclide imaging is complementary to CT and is used to help differentiate postoperative changes from infection. In the case of the painful joint replacement, in contrast, radionuclide studies are the primary diagnostic imaging modality for differentiating infection from other causes of prosthetic failure. Several tracers are available for imaging infection: 99mTc-diphosphonates, 67Ga-citrate, and 111In- and 99mTc-labeled leukocytes. At the moment, in immunocompetent patients, labeled leukocyte imaging is the radionuclide procedure of choice for detecting most infections. There are, unfortunately, significant limitations to the use of labeled leukocytes. The in vitro labeling process is labor intensive, is not always available, and involves direct handling of blood products. For musculoskeletal infection, the need to frequently perform complementary marrow or bone imaging adds complexity and expense to the procedure and is an inconvenience to patients. Considerable effort has therefore been devoted to the search for alternatives to this procedure, including in vivo methods of labeling leukocytes, 18F-FDG PET, and radiolabeled antibiotics. This article reviews the current status of nuclear medicine infection imaging and the potential of a murine monoclonal antigranulocyte antibody, fanolesomab, that is currently under investigation. Upon completion of this article, the reader will be familiar with the physical characteristics and uptake mechanisms of tracers currently approved for infection imaging, the indications for the uses of these tracers, and the characteristics and potential indications for a murine monoclonal antigranulocyte antibody under investigation.

KW - Antigranulocyte antibodies

KW - Bone

KW - Gallium

KW - Infection

KW - Infectious disease

KW - Labeled leukocytes

KW - Monoclonal antibodies

UR - http://www.scopus.com/inward/record.url?scp=12244301147&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12244301147&partnerID=8YFLogxK

M3 - Article

C2 - 15175400

AN - SCOPUS:12244301147

VL - 32

SP - 47

EP - 57

JO - Journal of Nuclear Medicine Technology

JF - Journal of Nuclear Medicine Technology

SN - 0091-4916

IS - 2

ER -